The goal of the Centralized Histopathology Laboratory (CHPL) is to provide histologic services to investigators at M.D. Anderson Cancer Center. The CHPL supplies technical support and consultation, develops or applies appropriate techniques, and maintains the consistency and high quality needed to perform these techniques. The CHPL is currently located in the Department of Pathology in 375 feet/2. Because of the increasing emphasis on in vivo systems in cancer biology and developmental biology, the number of laboratories using tissue specimens, transgenic mice, and gene-knockout technologies has increased dramatically. To provide efficient histology services to the institution, the CHPL will be expanded, and a second 370- feet/2 laboratory will be located in the R.E. """"""""Bob"""""""" Smith Research Building. The well-equipped and well-staffed CHPL processes fixed and frozen specimens for routine histologic analysis, immunohistochemical in situ hybridization (colorimetric procedures), and special staining for tissue sections and cells. The CHPL (both sites) is directed by Dr. Isaiah J. Fidler, and is accessible to all faculty, at M.D. Anderson Cancer Center, will preference given to investigators with peer-reviewed grants. Among the services provided are rapid preparation of high-quality standard histologic sections; application of special technologies as the need arises for selected projects, including preparation of frozen sections and histochemical, immunohistochemical, and tissue sections for in situ hybridization analysis; consultation with investigators to tailor technology to their special needs; and interpretation of histologic data. To access the CHPL, investigators make a formal application. After approval by the Director, the histotechnologist meets with the investigators to determine special needs of the study and the technical staff provides the histopathological services. The services are prioritized and coordinated to provide timely service. The development of new technologies that require additional equipment or special supplies has been funded by M.D. for specialized procedures such as in situ hybridization and 500 specially stained slides yearly. The increase in studies of transgenic mice and gene knockout mice will significantly increase the CHPL's workload, especially for special preparations such as serial sections of whole-embryos mounts. The CHPL is an essential component of the M.D. Anderson centralized research facilities that require histologic analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-26
Application #
6481852
Study Section
Project Start
2001-08-01
Project End
2002-06-30
Budget Start
Budget End
Support Year
26
Fiscal Year
2001
Total Cost
$254,104
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Dutcher, Giselle M A; Bilen, Mehmet Asim (2018) Therapeutic Vaccines for Genitourinary Malignancies. Vaccines (Basel) 6:
Kurnit, Katherine C; Dumbrava, Ecaterina E Ileana; Litzenburger, Beate et al. (2018) Precision Oncology Decision Support: Current Approaches and Strategies for the Future. Clin Cancer Res 24:2719-2731
Duplisea, Jonathan J; Mokkapati, Sharada; Plote, Devin et al. (2018) The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. World J Urol :
Jordan, V Craig (2018) Tamoxifen Resistance Trumped and Oral Selective Estrogen Receptor Degraders Arrive. Clin Cancer Res 24:3480-3482
Pantano, Naitielle; Hunt, Brady; Schwarz, Richard A et al. (2018) Is Proflavine Exposure Associated with Disease Progression in Women with Cervical Dysplasia? A Brief Report. Photochem Photobiol 94:1308-1313
Mehrvarz Sarshekeh, Amir; Xiong, Henry Q; Iizuka, Kenzo et al. (2018) Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer. Invest New Drugs 36:895-902
Lang, Frederick F; Conrad, Charles; Gomez-Manzano, Candelaria et al. (2018) Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. J Clin Oncol 36:1419-1427
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Talluri, Rajesh; Shete, Sanjay (2018) An approach to estimate bidirectional mediation effects with application to body mass index and fasting glucose. Ann Hum Genet 82:396-406
Bhadra, Anindya; Rao, Arvind; Baladandayuthapani, Veerabhadran (2018) Inferring network structure in non-normal and mixed discrete-continuous genomic data. Biometrics 74:185-195

Showing the most recent 10 out of 12418 publications